Targeted Genetics Cuts 3 Directors

Xconomy Seattle — 

Targeted Genetics, the Seattle-based developer of gene therapies, said today that three of the six members of its board of directors have stepped down. They departures aren’t because of a boardroom disagreement, but are intended to help save costs, Targeted said in a statement. Joseph Davie, Roger Hawley, and Nelson Levy have left the board, while Jeremy Curnock Cook, Michael Perry, and CEO Susan Robinson are keeping their board seats. The company has also made layoffs, and de-listed from the NASDAQ as part of its efforts to save cash.